After compulsory licensing: Coming issues in Canadian pharmaceutical policy and politics

Health Policy

Volumn 40, Issue 1, 1997, Pages 69-80

  Lexchin, Joel ^a,b,c  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b University of Toronto ^*  (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Canada; compulsory licensing; drug prices; patents; pharmaceutical research and development

Indexed keywords

CANADA; DRUG COST; DRUG RESEARCH; HEALTH CARE POLICY; HUMAN; LICENSING; POLITICS; REVIEW;

EID: 0030896346     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8510(96)00886-X     Document Type: Article

References (44)

1. Shulman, S.R. and Richard, B.W., The 1987 Canadian patent law amendments: revised pharmaceutical compulsory licensing provisions, Food, Drug and Cosmetic Law Journal, 43 (1988) 745-757.
2. Gorecki, P.K., Regulating the Price of Prescription Drugs in Canada: Compulsory Licensing, Product Selection, and Government Reimbursement Programmes, Technical Report No. 8, Economic Council of Canada, Ottawa, 1981.
3. Restrictive Trade Practices Commission, Report Concerning the Manufacture, Distribution and Sale of Drugs, Queen's Printer, Ottawa, 1963.
4. Royal Commission on Health Services, Report, Queen's Printer, Ottawa, 1964.
5. Canada, House of Commons, Second (Final) Report of the Special Committee of the House of Commons on Drug Costs and Prices, Queen's Printer, Ottawa, 1967.
6. Lexchin, J., Pharmaceuticals, patents and politics: Canada and Bill C-22, International Journal of Health Services, 23 (1983) 147-160.
7. Commission of Inquiry on the Pharmaceutical Industry, Report, Supply and Services Canada, Ottawa, 1985.
8. Patented Medicine Prices Review Board, 8th annual report for the year ended December 31, 1995, Supply and Services Canada, Ottawa, 1996.
9. Department of Foreign Affairs and International Trade and Industry Canada, The Case for Investing in Canada: Assessing Excellence in Canadian Pharmaceutical Research and Development, Ottawa, 1996.
10. Taylor, K.M., The impact of the pharmaceutical industry's clinical research programs on medical education, practice and researchers in Canada: a discussion paper, In: Canadian Pharmaceutical Research and Development: Four Short-term Studies, Industry, Science and Technology Canada, Ottawa, 1991.
11. Pharmaceutical Manufacturers Association of Canada, Annual Review 1994: The Challenge of Change, Ottawa, 1994.
12. Berkowitz, P., After slow start, project to channel drug company funds to universities builds steam, Canadian Medical Association Journal, 155 (1996) 318-20.
13. Kondro, W., Canada's MRC and drug industry try to make amends, Lancet, 347 (1996) 1478.
14. Legislative Committee on Bill C-22, Minutes of proceedings and evidence of the legislative committee on Bill C-22, Supply and Services Canada, Ottawa, Issue No. 3, January 20, 1987.
15. Statistics Canada, Industry Research and Development Statistics, Supply and Services Canada, Ottawa, various years.
16. Pharmaceutical Manufacturers Association of Canada, Towards Canadian pharmaceutical patent law reform, Ottawa, November 1992.
17. Pharmaceutical Manufacturers Association of Canada, 1988-1993: A Five-year Report on the Canadian Brand-name Pharmaceutical Industry, Ottawa, September 1993.
18. Lexchin, J., The effect of generic competition on the price of prescription drugs in the Province of Ontario, Canadian Medical Association Journal, 148 (1993) 35-38.
19. Schondelmeyer, S.W., The cost of Bill C-91: An Economic Impact Analysis of the Elimination of Compulsory Licensing of Pharmaceuticals in Canada, Canadian Drug Manufacturers Association, January 1993.
20. Baird, P.A., Funding Medical and Health-related Research in the Public Interest, Canadian Medical Association Journal, 155 (1996) 299-301.
21. Decision on patent dedication, Patented Medicine Prices Review Board Bulletin, Issue No. 17, October 1995.
22. Patented Medicine Prices Review Board, International price comparison of the top 200 selling patented drug products sold in Canada, Publication No. S-9302, Ottawa, March 1993.
23. Patented Medicine Prices Review Board, The top 200 selling patented drug products in Canada (1994), Publication No. S-9607, Ottawa, February 1996.
24. Balasubramaniam, K., Retail drug prices in the Asia-Pacific region. HAI News No. 86, December 1995, supplemental tables.
25. Green Shield Canada, A Report on Drug Costs. Toronto, October 1994.
26. Lexchin, J., Prescribing and drug costs in the province of Ontario. International Journal of Health Services, 22 (1992) 471-487.
27. Ministry of Health Ontario, Ontario Guidelines for Economic Analysis of Pharmaceutical Products, Queen's Printer for Ontario, Toronto, 1994.
28. Canadian Coordinating Office for Health Technology Assessment, Guidelines for Economic Evaluation of Pharmaceuticals: Canada, 1st edition, Ottawa, November 1994.
29. Vaughan, P., New Canadian institute to evaluate new drugs. Lancet, 346 (1995) 567.
30. Evans, R.G., Manufacturing consensus, marketing truth: guidelines for economic evaluation, Annals of Internal Medicine, 123 (1995) 59-60.
31. Soumerai, S.B., and Avorn, J., Economic and policy analysis of university-based drug 'detailing,' Medical Care, 24 (1986) 313-331.
32. Ray, W.A., Schaffner, W., and Federspiel, C.F., Persistence of improvement in antibiotic prescribing in office practice, Journal of the American Medical Association, 253 (1985) 1774-1776.
33. Rokstad, K., Straand, J. and Fugelli, P., Can drug treatment be improved by feedback on prescribing profiles combined with therapeutic recommendations? A prospective, controlled trial in general practice, Journal of Clinical Epidemiology, 48 (1995) 1061-1068.
34. Murray, M., Australian national drug policies: facilitating or fragmenting health? Development Dialogue, No. 1: 149-192, 1995.
35. Michols, D. and Lemay, P., Consultation paper on a national pharmaceutical strategy, Drugs Directorate, Health Canada, October 1994.
36. The drug approval system in Canada: an urgent need for change, PMAC News, May 1995: 1-4.
37. Lexchin, J., Who needs faster drug approval times in Canada: the public or the industry?, International Journal of Health Services, 24 (1994) 253-264.
38. Bueckert, D., Drug makers won't guarantee research funds, Ottawa Citizen, January 20, 1993: p. A3.
39. Erola, J.A., Presentation to the Group Insurance Section's Annual Forum, Toronto, October 1, 1992.
40. Grabowski, H., and Vernon, J., A new look at the returns and risks to pharmaceutical R and D, Management Science, 36 (1990) 804-21.
41. DiMasi, J.A., Hansen, R.W., Grabowski, H.G., and Lasagna, L., Cost of innovation in the pharmaceutical industry, Journal of Health Economics, 10 (1991) 107-142.
42. Office of Technology Assessment, Pharmaceutical R and D: Costs, Risks and Rewards, U.S. Government Printing Office, Washington, D.C., 1993 (Cat. No. OTA-H-522).
43. Vincent, D., Blood probe grills ex-bureaucrats, Toronto Star, November 4, 1995, p. A16.
44. Lexchin, J., Drug makers and drug regulators: too close for comfort. A study of the Canadian situation, Social Science and Medicine, 31 (1990) 1257-1263